直覺手術 (ISRG) 2013 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, good afternoon. Thank you for standing by, and welcome to the Intuitive Surgical quarter one 2013 earnings release conference call. At this time, all lines are in a listen only mode. Later there will be an opportunity for your questions, and instructions will be given at that time. (Operator instructions). As a reminder, today's conference is being recorded.

    各位女士、先生們,下午好。感謝各位耐心等候,歡迎參加直覺外科(Intuitive Surgical)2013 年第一季財報發布電話會議。目前所有線路皆為僅收聽模式。稍後將提供提問機會,屆時會提供相關指示。(接線員指示)。提醒各位,今天的會議將被錄音。

  • I would now like to turn the conference over to our host, Senior Director of Finance, Mr. Calvin Darling. Please go ahead.

    現在我想把會議交給我們的主持人——財務資深總監 Calvin Darling 先生。請開始。

  • Calvin Darling - Sr. Dir., Finance

    Calvin Darling - Sr. Dir., Finance

  • Good afternoon and welcome to Intuitive Surgical's first-quarter earnings conference call. With me today we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Aleks Cukic, our Vice President of Strategic Planning.

    下午好,歡迎參加直覺外科第一季財報電話會議。今天與我一同出席的有:總裁暨執行長 Gary Guthart;財務長 Marshall Mohr;以及策略規劃副總裁 Aleks Cukic。

  • Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

    在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中詳加說明。提醒潛在投資人勿過度依賴此類前瞻性陳述。

  • Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the audio archive section under our Investor Relations page.

    請注意,本次電話會議的錄音回放將可於 intuitivesurgical.com 網站的「投資人關係」頁面下之音訊存檔區收聽。

  • In addition, today's press release has been posted to our website.

    此外,今天的新聞稿已發布於我們的網站。

  • Today's format will consist of providing you with highlights of our first-quarter results as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our first-quarter financial results. Aleks will discuss marketing and clinical highlights. Then I will provide an update to our financial forecast for 2013.

    今天的流程將先提供我們第一季業績重點(如同今日稍早發布之新聞稿所述),接著進行問答。Gary 將說明本季的業務與營運重點。Marshall 將回顧第一季財務結果。Aleks 將討論行銷與臨床重點。接著我將更新我們對 2013 年的財務預測。

  • Finally, we will host a question and answer session. With that, I will turn it over to Gary.

    最後,我們將進行問答時間。接下來我把時間交給 Gary。

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • Thank you for joining us today. Before we get started describing our quarterly performance, I would like to make a few comments regarding current events. As you know, we are in the midst of a concerted effort by critics of robotic surgery to challenge the benefit it brings to patients, the value it brings to the medical community and the quality of our organization. While taking these allegations very seriously, we remain deeply committed to developing and providing products that in a surgeon's hands ease the burden of surgery for patients who can benefit from them. We take pride in the benefits provided by our systems, demonstrated in numerous large-scale population studies comparing da Vinci surgery to open surgery for several different procedures. We are confident that those who invest their time in a serious review of the clinical literature on da Vinci will find ample evidence of the benefit it brings to patients, surgeons, hospitals and the medical community at large.

    感謝各位今天加入我們。在開始說明本季表現之前,我想先就近期事件做幾點說明。如各位所知,我們正面臨機器人手術批評者的集體行動,試圖質疑其對病患的效益、對醫療界的價值,以及我們組織的品質。我們非常嚴肅看待這些指控,同時仍堅定致力於研發並提供產品,使外科醫師在使用時能減輕手術對可受益病患的負擔。我們以系統所帶來的效益為榮,這些效益已在多項大型族群研究中獲得證實;相關研究比較了達文西手術與傳統開放式手術在多種不同術式上的表現。我們相信,凡是願意投入時間嚴謹檢視達文西相關臨床文獻者,將能找到充分證據,證明其為病患、外科醫師、醫院以及整體醫療社群帶來的效益。

  • To date, over 1 million patients have chosen da Vinci minimally invasive surgery, surgery that would have otherwise been performed through an open incision.

    截至目前,已有超過 100 萬名病患選擇達文西微創手術;若非如此,這些手術原本將以開放式切口方式進行。

  • Turning to our performance in the quarter, we experienced strong growth in general surgery, slower growth in gynecology and a return to stability in urology. This resulted in an 18% procedure growth over 2012. The first quarter of 2013 had one fewer surgery day than 2012. Taking this into account, normalized procedure growth improves to approximately 20%.

    回到本季表現,我們在一般外科呈現強勁成長,婦科成長較慢,而泌尿科則回到穩定狀態。因此,相較 2012 年,手術量成長 18%。2013 年第一季比 2012 年少了一個手術日。將此因素納入考量後,標準化後的手術量成長約提升至 20%。

  • General surgery growth was led by single-site cholecystectomy and colon and rectal procedures. Gynecologic procedures for benign indications are typically seasonally slower in the first quarter. However, we experienced slower than expected growth in benign hysterectomies in this first quarter of 2013.

    一般外科的成長主要由單孔膽囊切除術,以及結腸與直腸手術所帶動。因良性適應症進行的婦科手術通常在第一季呈現季節性較慢。然而,在 2013 年第一季,我們觀察到良性子宮切除術的成長低於預期。

  • Worldwide urology procedures experienced solid growth, aided by the stabilizing of prostatectomy procedures in the United States. Considering the above, procedure growth for the quarter came in at the lower range of our expectations. Alex will provide additional procedure commentary later in the call.

    全球泌尿科手術量呈現穩健成長,其中美國前列腺切除術手術量趨於穩定亦有所助益。綜合上述,本季手術量成長落在我們預期區間的較低端。Alex 將在稍後提供更多手術量相關評論。

  • Turning to markets outside of the United States, our first quarter of SI system sales to Japan went well with encouraging early customer demand for the system. We are supporting surgical societies in Japan in their efforts to obtain national reimbursement for procedures beyond prostatectomy.

    就美國以外市場而言,我們第一季在日本的 SI 系統銷售表現良好,且客戶對該系統的早期需求令人鼓舞。我們正支持日本的外科醫學會,協助其爭取前列腺切除術以外術式的全國性給付(reimbursement)。

  • In Europe, procedures and system sales followed seasonal trends and showed modest growth. We continue to build our team in Europe, and I am pleased with our organizational development over the past few quarters. Overall, operating highlights for the first quarter are as follows.

    在歐洲,手術量與系統銷售符合季節性趨勢並呈現溫和成長。我們持續擴充歐洲團隊,且我對過去幾季的組織發展感到滿意。整體而言,第一季的營運重點如下。

  • Procedures grew 18% over the first quarter of 2012. Adjusting for the number of procedure days in the quarter, normalized growth was approximately 20%. We sold 164 da Vinci Surgical Systems, up from 140 during the first quarter of last year. Total revenue was $611 million, up 23% over last year. Instruments and accessories revenue increased to $261 million, up 26% over Q1 of 2012. Total recurring revenue grew to $356 million, up 23% from prior year and comprising 58% of total revenue. We generated an operating profit of $285 million before non-cash stock option expense, up 27% from the first quarter of last year. Net income was $189 million, up 32% over last year.

    手術量較 2012 年第一季成長 18%。若依本季手術日數調整,標準化後成長約為 20%。我們售出 164 套達文西手術系統,高於去年第一季的 140 套。總營收為 6.11 億美元,較去年成長 23%。器械與配件營收增至 2.61 億美元,較 2012 年第一季成長 26%。總經常性收入增至 3.56 億美元,較去年成長 23%,占總營收 58%。扣除非現金股票選擇權費用前,我們的營業利益為 2.85 億美元,較去年第一季成長 27%。淨利為 1.89 億美元,較去年成長 32%。

  • Earnings per share for the quarter were $4.56 compared to $3.50 in the first quarter of 2012. We ended the quarter with $3,116,000,000 in cash and investments, up $196 million from last quarter. Significant cash outlays in the quarter included $17 million investment in fixed assets and intellectual property. We repurchased $146 million worth of our shares in the quarter.

    本季每股盈餘為 4.56 美元,2012 年第一季為 3.50 美元。本季末現金與投資合計為 31.16 億美元,較上季增加 1.96 億美元。本季主要現金支出包括 1,700 萬美元,用於固定資產與智慧財產投資。本季我們回購了 1.46 億美元的公司股票。

  • Our product development teams continued to make good progress. This quarter we initiated our controlled rollout for single-site hysterectomy and [uferectomy]. Leading surgeons are optimizing their procedure choreography, and we plan to expand our installations at a measured pace through the year. Early surgeon and patient interest in Single-Site for hysterectomy is high.

    我們的產品開發團隊持續取得良好進展。本季我們啟動單孔子宮切除術與 [uferectomy] 的受控推廣(controlled rollout)。領先的外科醫師正優化其手術流程編排,我們計畫在全年以審慎的步調擴大裝機。外科醫師與病患對單孔子宮切除術的早期興趣很高。

  • We have also initiated our first clinical cases with our da Vinci stapler. As we have mentioned previously, our first stapling product is focused on colorectal surgery. Early clinical results and surgeon feedback on use of the stapler are very encouraging. Given the subtleties involved in the use and manufacture of surgical staplers, a rollout plan for the stapler will be conservative for the year.

    我們也已啟動達文西縫合器(stapler)的首批臨床案例。如先前所提,我們的第一款縫合產品聚焦於大腸直腸手術。早期臨床結果以及外科醫師對縫合器使用的回饋都非常令人鼓舞。鑑於手術縫合器在使用與製造上涉及諸多細微之處,今年對縫合器的推廣計畫將採取保守策略。

  • Turning to system and imaging developments, we continue to invest in expanding indications for Firefly Fluorescence Imaging and in deepening our product offerings in support of system training. We are currently answering FDA questions regarding expanding Firefly indications to include biliary imaging. The intent of this indication is to allow surgeons to image the common bile duct in real-time during cholecystectomy.

    在系統與影像技術發展方面,我們持續投資以擴大 Firefly 螢光影像(Fluorescence Imaging)的適應症,並深化我們在系統訓練支援方面的產品供給。目前我們正在回覆 FDA 對於擴大 Firefly 適應症、納入膽道影像(biliary imaging)的相關問題。此適應症的目的,是讓外科醫師在進行膽囊切除術時,能即時影像顯示總膽管。

  • On the simulation front, we have added new surgical skill modules to our simulator through our development partnerships. Our medical research team is working with academic centers worldwide on face, content and construct validity studies of the da Vinci Skills Simulator. Early publications of these validations are positive.

    在模擬器方面,我們透過開發合作夥伴關係,已在我們的模擬器中新增新的外科技能模組。我們的醫學研究團隊正與全球各地的學術中心合作,針對達文西技能模擬器(da Vinci Skills Simulator)進行表面效度、內容效度與建構效度研究。這些驗證的早期發表結果正面。

  • Lastly, we are initiating our first clinical sites configured with da Vinci Connect over the next few months. Da Vinci Connect is our system for remote proctoring. Remote proctoring uses Internet-based conferencing technology to allow a distant surgeon to participate in the da Vinci case with a surgeon on an SI console through video, voice and illustration. It is intended to augment surgical proctoring by lowering the time, distance and cost barriers to expert participation during a surgeon's learning period.

    最後,我們將在未來幾個月內啟動首批配置達文西 Connect(da Vinci Connect)的臨床據點。達文西 Connect 是我們用於遠端監督指導(remote proctoring)的系統。遠端監督指導使用以網際網路為基礎的會議技術,讓遠端外科醫師可透過影像、語音與標註示意,與在 SI 主控台上的外科醫師一同參與達文西手術案例。其目的在於透過降低專家在外科醫師學習期間參與所需的時間、距離與成本障礙,強化手術監督指導。

  • We are also investing in the construction of two new training centers that are expected to become operational this year, one increasing the capacity of our training center at our California headquarters and a second new facility in Atlanta to serve our customers in the East. As we enter new surgical markets and drive into new product arenas, we continue to invest in building our team and expanding partnerships and acquiring those technologies that can make a difference to robotic surgery.

    我們也正在投資興建兩座新的訓練中心,預計將於今年投入營運:一座將提升我們加州總部訓練中心的容量,另一座位於亞特蘭大的新設施,將服務東部地區的客戶。隨著我們進入新的外科市場並拓展至新的產品領域,我們持續投資於團隊建置、擴大合作夥伴關係,並取得能對機器人手術帶來改變的技術。

  • This quarter we added 118 people to our team, predominantly in sales, manufacturing and R&D, bringing our total team to 2480 employees.

    本季我們新增了 118 名團隊成員,主要在銷售、製造與研發領域,使員工總數達到 2,480 人。

  • I will now pass the time over to Marshall, our Chief Financial Officer.

    接下來我把時間交給我們的財務長 Marshall。

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • Thank you, Gary. Our first-quarter revenue was $611 million, up 23% compared with $495 million for the first quarter of 2012 and roughly equal to the $609 million last quarter. First-quarter revenues by product category were as follows.

    謝謝你,Gary。我們第一季營收為 6.11 億美元,較 2012 年第一季的 4.95 億美元成長 23%,且與上一季的 6.09 億美元大致相當。第一季依產品類別的營收如下。

  • First-quarter instrument and accessory revenue was $261 million, up 26% compared to $208 million for the first quarter of 2012 and up 3% compared with $254 million in the fourth quarter of 2012. The year-over-year increase in instrument and accessory revenue was driven by procedure growth of 18%, sales of new products including Single-Site Vessel Sealer and Firefly and higher stocking orders associated with higher system unit sales. The 18% procedure growth was impacted by one additional operating day in the first quarter of 2012, reflecting Leap Year. Excluding the impact of Leap Year, procedure growth would have been approximately 20%.

    第一季器械與配件營收為 2.61 億美元,較 2012 年第一季的 2.08 億美元成長 26%,較 2012 年第四季的 2.54 億美元成長 3%。器械與配件營收的年增主要由 18% 的手術量成長、新產品(包括 Single-Site Vessel Sealer 與 Firefly)的銷售,以及與較高系統出貨量相關的較高備貨訂單所帶動。這 18% 的手術量成長受到 2012 年第一季多出一天手術日的影響,反映閏年因素。若排除閏年影響,手術量成長約為 20%。

  • Procedure growth also reflects seasonality associated with benign hysterectomies, which was more pronounced in 2013 compared with 2012 as we achieve deeper penetration in this market. The year-over-year procedure growth was led by US general surgery and oncology procedures, partially offset by lower US dVPs of approximately 11%. US dVP procedures are approximately 4% higher than the fourth quarter of 2012.

    手術量成長亦反映與良性子宮切除術相關的季節性;隨著我們在此市場滲透更深,2013 年的季節性較 2012 年更為明顯。年增的手術量成長主要由美國一般外科與腫瘤手術帶動,但部分被美國 dVP 手術量約 11% 的下降所抵銷。美國 dVP 手術量較 2012 年第四季約高 4%。

  • The sequential increase in instrument and accessory revenue compared with the last quarter was driven by the timing of customer orders and new product revenue associated with the increased usage of Firefly, Vessel Sealer and Single-Site. Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $2110 per procedure, which is higher than the $1990 realized in the first quarter of last year and the $2050 realized in the fourth quarter. The sequential increase from the fourth quarter of 2012 to the first quarter of 2013 was driven primarily by the timing of customer orders.

    相較上一季,器械與配件營收的季增主要由客戶下單時點,以及因 Firefly、Vessel Sealer 與 Single-Site 使用增加所帶來的新產品營收所驅動。每例手術實現的器械與配件營收(含初始備貨訂單)約為每例 2,110 美元,高於去年第一季的每例 1,990 美元以及第四季的每例 2,050 美元。2012 年第四季至 2013 年第一季的季增,主要由客戶下單時點所致。

  • First-quarter 2013 systems revenue of $256 million increased 24% compared with $207 million for the first quarter of 2012 and decreased 3% compared with $265 million for the fourth quarter of 2012. Our higher systems revenue compared to the first quarter of last year was driven by higher unit sales and a higher average selling price. We sold 164 systems in the first quarter of 2013 compared with 140 systems in the first quarter of last year and 175 systems in the seasonally stronger fourth quarter of 2012. Our first-quarter 2013 system sales included 25 systems into Japan where we launched the da Vinci SI at the start of this year. We sold seven systems into Japan during the first quarter of 2012 and 10 last quarter.

    2013 年第一季系統營收為 2.56 億美元,較 2012 年第一季的 2.07 億美元成長 24%,較 2012 年第四季的 2.65 億美元下降 3%。相較去年第一季,我們較高的系統營收主要由較高的出貨台數與較高的平均售價所帶動。2013 年第一季我們銷售 164 套系統,去年第一季為 140 套,而在季節性較強的 2012 年第四季為 175 套。2013 年第一季的系統銷售包含銷往日本的 25 套;我們於今年年初在日本推出達文西 SI(da Vinci SI)。2012 年第一季我們在日本售出 7 套,上季售出 10 套。

  • Our first-quarter average selling price per system was $1.55 million compared with $1.47 million realized in the first quarter of 2012 and the $1.49 million realized last quarter. ASPs include all da Vinci models, all simulators and Firefly when configured with the system and exclude upgrades. Our higher first-quarter 2013 ASP was driven by a higher proportion of dual-console configurations and a favorable geographic mix. 48 of the 164 first-quarter sales were dual-console models compared with 25 of 140 last year and 32 of 175 last quarter. 15 of the 25 units sold in Japan during the first quarter were dual-console models.

    第一季每套系統的平均售價為 155 萬美元,去年第一季為 147 萬美元,上季為 149 萬美元。平均售價(ASP)包含所有達文西機型、所有模擬器,以及在系統配置中搭配的 Firefly,並排除升級(upgrades)。2013 年第一季較高的 ASP 主要由雙主控台配置占比提高,以及有利的地理區域組合所帶動。第一季 164 套銷售中有 48 套為雙主控台機型,去年為 140 套中的 25 套,上季為 175 套中的 32 套。第一季在日本售出的 25 套中,有 15 套為雙主控台機型。

  • We sold 97 simulators during the quarter, mostly in conjunction with new system sales, compared with 102 last year and 115 last quarter. 39 of our first-quarter 2013 system sales involve trade-ins comprised of 30 da Vinci Ss and nine standard models. 46 of our first-quarter 2012 sales involved trade-ins, and 52 of our fourth-quarter 2012 sales involve trade-ins.

    本季我們售出 97 台模擬器,多數與新系統銷售一併出售;去年為 102 台,上季為 115 台。我們 2013 年第一季的系統銷售中,有 39 筆涉及以舊換新(trade-ins),包含 30 套 da Vinci S 與 9 套標準機型。2012 年第一季的銷售中有 46 筆涉及以舊換新,而 2012 年第四季的銷售中有 52 筆涉及以舊換新。

  • Service revenue increased to $94 million, up 17% compared with $81 million last year and up 4% compared with $91 million last quarter. The growth in service revenue was primarily driven by a larger system installed base.

    服務營收增至 9,400 萬美元,較去年 8,100 萬美元成長 17%,較上季 9,100 萬美元成長 4%。服務營收成長主要由更大的系統裝機基礎所帶動。

  • Total first-quarter recurring revenue, comprised of instruments, accessories and service revenue, increased to $356 million, up 23% compared with the first quarter of last year and up 3% compared with the fourth quarter of 2012. Recurring revenue represented 58% of total first-quarter revenue compared with 58% in the first quarter of last year and 57% last quarter.

    第一季經常性營收總額(由器械、配件與服務營收構成)增至 3.56 億美元,較去年第一季成長 23%,較 2012 年第四季成長 3%。經常性營收占第一季總營收的 58%,與去年第一季的 58% 相同,較上季的 57% 略高。

  • International results were as follows. First-quarter revenue outside of the United States was $453 million, up 47% compared with revenue of $105 million in the first quarter of last year and up 17% compared with revenue of $131 million in the fourth quarter of 2012. Our year-over-year and quarter-over-quarter international revenue growth was driven by higher da Vinci system sales into the Japanese market. First-quarter 2013 international procedure volume was approximately 14% higher than the first quarter of 2012 and 10% higher than the fourth quarter of 2012.

    國際市場表現如下。第一季美國以外地區營收為 4.53 億美元,較去年第一季的 1.05 億美元成長 47%,較 2012 年第四季的 1.31 億美元成長 17%。我們國際營收的年增與季增主要由日本市場達文西系統銷售增加所帶動。2013 年第一季國際手術量約較 2012 年第一季高 14%,較 2012 年第四季高 10%。

  • During the first quarter of 2013, we sold 49 systems outside of the US compared with 35 in the first quarter of 2012 and 42 last quarter. We sold 16 systems in Europe this quarter compared with 14 in the first quarter of 2012 and 24 last quarter.

    2013 年第一季,我們在美國以外地區售出 49 套系統,去年第一季為 35 套,上季為 42 套。本季我們在歐洲售出 16 套系統,去年第一季為 14 套,上季為 24 套。

  • Moving on to the remainder of the P&L, gross margin in the first quarter of 2013 was 71% compared with 71.9% during both the first and fourth quarters of 2012. Our lower first-quarter 2013 gross margin percentage resulted primarily from the impact of the medical device excise tax, partially offset by the favorable impact of higher system ASPs and higher service margins. Our first-quarter 2013 cost of sales included $6.5 million related to the medical device excise tax.

    接著看損益表其餘項目,2013 年第一季毛利率為 71%,相較 2012 年第一季與第四季的 71.9%。2013 年第一季毛利率較低主要是受到醫療器材消費稅(medical device excise tax)的影響,但部分被較高的系統 ASP 與較高的服務毛利率所帶來的有利影響抵銷。我們 2013 年第一季銷貨成本包含與醫療器材消費稅相關的 650 萬美元。

  • First-quarter 2013 operating expenses of $183 million were up 13% compared with the first quarter of 2012 and down 4% compared with the fourth quarter of 2012. Our higher year-over-year operating expenses were primarily driven by headcount additions. The sequential decrease in operating expenses was driven by lower variable compensation expense and the timing of engineering projects and other expenses.

    2013 年第一季營運費用為 1.83 億美元,較 2012 年第一季增加 13%,較 2012 年第四季下降 4%。我們營運費用年增主要是由於增加人力編制所致。營運費用的季減則是因為變動薪酬費用較低,以及工程專案與其他費用的認列時點所致。

  • First-quarter 2013 operating income was $251 million or 41% of sales compared with $193 million or 39% of sales last year and $248 million or 41% of sales for the fourth quarter of 2012. First-quarter 2013 operating income reflected $38 million of non-cash stock compensation expense compared with $34 million last year and $30 million last quarter.

    2013 年第一季營業利益為 2.51 億美元(占銷售額 41%),相較去年為 1.93 億美元(占銷售額 39%),2012 年第四季為 2.48 億美元(占銷售額 41%)。2013 年第一季營業利益包含 3,800 萬美元的非現金股票酬勞費用,相較去年為 3,400 萬美元、上季為 3,000 萬美元。

  • Our effective tax rate for the first quarter was 26% compared with 27% for the first quarter of 2012 and 31% last quarter. As anticipated, our first-quarter 2013 income tax expense included a discrete benefit of approximately $7.5 million for the reinstatement of the 2012 R&D tax credit, which became effective January 1 of this year.

    我們第一季的有效稅率為 26%,相較 2012 年第一季為 27%,上季為 31%。如預期,2013 年第一季所得稅費用包含約 750 萬美元的一次性(離散)利益,係因 2012 年研發(R&D)稅額抵減恢復適用,並自今年 1 月 1 日起生效。

  • Otherwise, our tax rate would have been 29%. Our tax provision for the first quarter of 2012 included a one-time benefit associated with domestic manufacturing tax credits, and otherwise, our tax rate in the quarter would have been 32%.

    若不計上述因素,我們的稅率將為 29%。我們 2012 年第一季的所得稅提列包含與國內製造業稅額抵減相關的一次性利益;若不計該項利益,當季稅率將為 32%。

  • Our net income was $189 million or $4.56 per share compared with $144 million or $3.50 per share last year and $175 million or $4.25 per share for the fourth quarter of 2012.

    我們淨利為 1.89 億美元或每股 4.56 美元,相較去年為 1.44 億美元或每股 3.50 美元,2012 年第四季為 1.75 億美元或每股 4.25 美元。

  • Now moving to cash flow, we ended the first quarter with cash and investments of $3.1 billion, up $196 million compared with December 31, 2012. The increase was driven by $258 million of cash flows from operations, plus $89 million from the exercise of stock options, partially offset by $146 million in stock buy backs and $17 million of capital and IP purchases.

    接著談現金流,我們第一季末的現金及投資為 31 億美元,較 2012 年 12 月 31 日增加 1.96 億美元。增加主要來自營運活動現金流入 2.58 億美元,加上員工行使股票選擇權帶來 8,900 萬美元,部分被 1.46 億美元的庫藏股回購及 1,700 萬美元的資本支出與智慧財產(IP)購置所抵銷。

  • During the first quarter, we bought back 299,000 shares at an average price of $487 per share.

    第一季期間,我們以每股平均 487 美元的價格回購 299,000 股。

  • As recently announced, our Board of Directors has increased our share buyback authorization by $1 billion. Including this latest authorization, we ended the quarter with approximately $1.2 billion of authorized share buybacks.

    如近期所宣布,我們董事會已將股票回購授權額度增加 10 億美元。包含此次最新授權在內,我們於季末尚有約 12 億美元的股票回購授權額度。

  • And with that, I would like to turn it over to Alex, who will go over our sales, marketing and clinical highlights.

    接下來,我想把時間交給 Alex,他將說明我們在銷售、行銷與臨床方面的重點。

  • Aleks Cukic - VP, Strategic Planning

    Aleks Cukic - VP, Strategic Planning

  • Thank you, Marshall. During the first quarter, we sold 164 da Vinci systems -- 115 in the United States, 16 into Europe and 33 into rest of world markets. As part of the 164 system sales, nine standard da Vinci systems and 30 da Vinci S systems were traded in for credit against sales for new da Vinci SI systems. We finished the quarter with a net 125 system additions to the installed base, bringing to 2710 the cumulative number of da Vinci systems worldwide, 1957 in the United States, 430 in Europe and 323 in rest of world markets.

    謝謝你,Marshall。第一季我們共售出 164 套達文西(da Vinci)系統——其中 115 套在美國、16 套在歐洲、33 套在世界其他市場。在這 164 套系統銷售中,有 9 套標準 da Vinci 系統與 30 套 da Vinci S 系統以舊換新,折抵購買新的 da Vinci SI 系統。本季我們的裝機基礎淨增加 125 套,使全球累計 da Vinci 系統數量達到 2,710 套,其中美國 1,957 套、歐洲 430 套、世界其他市場 323 套。

  • 75 of the 164 systems installed during the quarter represented repeat system sales to existing customers. In total, 162 of the 164 systems sold represented da Vinci SI or SIE systems, which included 48 dual-console systems. The 49 system sales internationally included 25 into Japan, four into France and three into Turkey.

    本季安裝的 164 套系統中,有 75 套為既有客戶的重複購買。總計而言,售出的 164 套系統中有 162 套為 da Vinci SI 或 SIE 系統,其中包含 48 套雙主控台系統。國際市場的 49 套系統銷售中,包括日本 25 套、法國 4 套、土耳其 3 套。

  • Clinically, Q1 year-over-year procedure growth was approximately 18%, led by the category of general surgery followed by GYN. General surgery growth was paced by cholecystectomy followed by colon and rectal resections.

    在臨床方面,第一季手術量年增約 18%,主要由一般外科帶動,其次為婦科(GYN)。一般外科的成長以膽囊切除術為主,其次為結腸與直腸切除術。

  • As Gary stated, procedure growth reflected seasonality, the reduction of selling days and a slower quarter for benign dVH. dVP, more specifically the rate of decline for US dVP, a topic extensively discussed, appears to be flattening out. US dVP was once again up on a sequential basis with a reduced rate of decline as compared to last year.

    如 Gary 所述,手術量成長反映季節性因素、可銷售天數減少,以及良性 dVH 表現較為疲弱的一季。dVP,尤其是美國 dVP 的下滑速度(這個議題已被廣泛討論),看起來正趨於持平。美國 dVP 再次呈現季增,且相較去年下滑幅度已縮小。

  • Overall, other urology, as well as international dVP, showed solid growth both on a sequential and on a year-over-year basis. Recently released new products continue to perform well, notably Single-Site, where customer feedback has been positive and sales have remained strong. Through Q1 2013, we have sold Single-Site instrument and accessory kits to approximately 630 US customers.

    整體而言,其他泌尿科手術以及國際 dVP,無論季比或年比皆呈現穩健成長。近期推出的新產品持續表現良好,尤其是 Single-Site;客戶回饋正面,銷售亦維持強勁。截至 2013 年第一季,我們已向約 630 家美國客戶銷售 Single-Site 器械與配件套組。

  • Our recently launched Vessel Sealer product has picked up clinical momentum with most of the interest coming from the specialties of colorectal, advanced general surgery and GYN. The customer adoption for both da Vinci Simulator and Firefly continues to expand with 97 customers purchasing a da Vinci Simulator and 69 customers purchasing Firefly systems as part of their initial system purchase this quarter.

    我們近期推出的 Vessel Sealer 產品在臨床端的動能持續提升,且多數興趣來自大腸直腸科、進階一般外科與婦科(GYN)等專科。da Vinci Simulator 與 Firefly 的客戶採用率持續擴大;本季有 97 位客戶在首次購機時同時購買 da Vinci Simulator,另有 69 位客戶在首次購機時購買 Firefly 系統。

  • In addition, we have begun a phased rollout of the da Vinci surgical stapling system, as well as our Single-Site hysterectomy products. These rollouts will be expanded in a measured fashion, so we do not expect them to contribute materially to 2013 revenue.

    此外,我們已開始分階段推出 da Vinci 手術縫合釘合系統(surgical stapling system),以及 Single-Site 子宮切除術產品。這些推出將以審慎方式逐步擴大,因此我們預期其對 2013 年營收不會有重大貢獻。

  • During the quarter, several hundred robotic abstracts and papers representing a variety of surgical specialties were published within various peer-reviewed journals, while quarterly clinical conferences produced several live da Vinci procedure transmissions, postgraduate robotic courses, podium presentations and clinical poster sessions. As many of you know, we are currently participating at the annual SAGES conference, which is taking place in Baltimore. The surgeon support we received at this conference thus far has been positive.

    本季期間,數百篇涵蓋多種外科專科的機器人手術摘要與論文發表於各類同儕審查期刊;同時,季度臨床會議也進行了多場 da Vinci 手術的現場轉播、研究生後機器人課程、講台報告與臨床海報展示。如各位所知,我們目前正在參與於巴爾的摩舉行的年度 SAGES 會議。截至目前,我們在本次會議所獲得的外科醫師支持反應正面。

  • Much of the critical press we received has been directed toward the cost efficacy of da Vinci within the specialty of GYN and, more specifically, within its use to treat benign conditions.

    我們所受到的許多批評性報導,主要聚焦於 da Vinci 在婦科(GYN)領域的成本效益,且更具體地說,是其用於治療良性疾病時的成本效益。

  • To be clear, we believe strongly that one of our greatest growth opportunities consists of converting open hysterectomy to dVH. da Vinci has shown itself as a very capable and cost effective tool in expanding minimally invasive surgery to a far greater number of patients who would otherwise have undergone an open surgical procedure. Open hysterectomy is where we focus. Open hysterectomy represents the largest component of our target market growth. Open hysterectomy conversions is where we deliver high patient value.

    需要說明的是,我們堅信我們最大的成長機會之一,是將開腹子宮切除術轉換為 dVH。da Vinci 已證明自己是一項非常有能力且具成本效益的工具,可將微創手術擴展至更多病患;這些病患若非如此,原本將接受開腹手術。我們的重點在於開腹子宮切除術。開腹子宮切除術是我們目標市場成長中最大的組成部分。在開腹子宮切除術的轉換上,我們能為病患提供高價值。

  • Unfortunately, most of the media, as well as the ACOG commentary, were focused on da Vinci's economic profile versus either vaginal surgery or simple laparoscopy. For decades, the popularity of vaginal and laparoscopy approaches to hysterectomy paled in comparison to the number of open hysterectomies being performed within the United States, which clearly explains the motivation driving our dVH opportunity.

    不幸的是,多數媒體以及 ACOG 的評論,聚焦於 da Vinci 相較於陰道手術或簡單腹腔鏡手術的經濟性表現。數十年來,在美國進行的開腹子宮切除術數量遠高於陰道途徑與腹腔鏡途徑,這也清楚解釋了推動我們 dVH 機會的動機。

  • In a recent edition of the Journal, Gynecologic Surgery, a European study discussed this very issue. The study emanated out of Cork University maternity hospital in Cork, Ireland, an extremely cost-sensitive market with national austerity measures in place.

    在近期一期《Gynecologic Surgery(婦科手術)》期刊中,一項歐洲研究討論了這個議題。該研究來自愛爾蘭科克(Cork)的科克大學婦產醫院(Cork University maternity hospital);該市場對成本極為敏感,且正實施全國性的財政緊縮措施。

  • In the analysis, Cork U computed and compared hysterectomy-specific hospitalization costs between their hospital and a similarly sized reference hospital with a similar hysterectomy treatment mix. The hysterectomy treatment mix in these hospitals included open, midline incision, lower transverse incision, LAVH and vaginal hysterectomy. They determined that on average an open hysterectomy performed through a midline incision required an eight-day hospitalization, six days for a hysterectomy performed through a lower transverse incision, three days for an LAVH and three days for a vaginal hysterectomy. They computed costs for a day of hospitalization to be approximately EUR534.

    在該分析中,科克大學(Cork U)計算並比較其醫院與一家規模相近、且子宮切除術治療組合相似的參考醫院之「子宮切除術特定」住院成本。這些醫院的子宮切除術治療組合包括開腹、正中切口、下腹橫切口、LAVH 以及陰道子宮切除術。他們判定,平均而言,採正中切口的開腹子宮切除術需住院 8 天;採下腹橫切口的子宮切除術需 6 天;LAVH 需 3 天;陰道子宮切除術亦需 3 天。他們估算每日住院成本約為 534 歐元。

  • Cork University acquired their da Vinci system in 2008, whereas the reference hospital did not. Following the inclusion of da Vinci, Cork University discovered that their dVH patients were spending only two days in the hospital, and GYN beds were being consumed for fewer days. They also reported that the rate of open surgery has been reducing by 10% per year at Cork following the introduction of dVH and is projected to represent only 5% of the total hysterectomies performed during the final year of the study, as compared to 35% open hysterectomy rate in the non-da Vinci reference hospital.

    科克大學於2008年購置其達文西系統,而作為參考的醫院則未購置。在導入達文西之後,科克大學發現其 dVH 病患住院僅兩天,且婦科(GYN)病床占用天數也減少。他們亦報告指出,在科克於引進 dVH 後,開腹手術比率每年下降10%,並預計在研究最後一年,開腹手術僅占所進行子宮切除術總數的5%,相較之下,未使用達文西的參考醫院開腹子宮切除術比率為35%。

  • When comparing the current mix and extrapolating over an annual basis, 280 hysterectomies, the bed-day rate is reduced from 1134 days to 756 days when incorporating da Vinci, which represents a potential annual savings of over EUR200,000. In the author's comments they stated, and I quote, In 2009 the American Congress of Obstetricians and Gynecologists released a statement recommending vaginal hysterectomy as the approach of choice for benign hysterectomies due to reduced operating times when compared to the laparoscopic approach. However, they note that laparoscopic surgery is an alternative to vaginal hysterectomy, is not -- when vaginal hysterectomy is not feasible or indicated. Increasing the rate of vaginal surgery decreases the cost of the surgery compared to the open approach due to reduced length of stay. Consideration must be given to the fact that not all surgeries are amendable to the vaginal approach, close quote.

    若比較目前的組合並按年度推估(每年280例子宮切除術),納入達文西後,床日率可由1,134天降至756天,代表每年可望節省超過20萬歐元。作者在評論中表示(引述如下):2009年,美國婦產科醫師學會發布聲明,建議對良性子宮切除術以陰道子宮切除術作為首選方式,因其手術時間較腹腔鏡方式更短。然而,他們也指出,當陰道子宮切除術不可行或不適用時,腹腔鏡手術可作為替代方案。提高陰道手術比例可因住院天數縮短而降低相較於開腹方式的手術成本。必須考量並非所有手術都適合採陰道途徑(引述完畢)。

  • One could argue that the same commentary would pertain to the laparoscopic approach in that it, too, has remained in the minority due to clinical and/or technical challenges. The authors concluded their paper by stating, and I quote, robotic surgery is associated with reduced hospital stay compared with open surgery. While the initial outlay is expensive, the increased number of patients amendable to this minimally access approach compared with conventional keyhole surgery has the potential for financial savings, close quote.

    有人可能會主張,同樣的評論也適用於腹腔鏡途徑,因其亦因臨床及/或技術挑戰而長期仍屬少數。作者在論文結語中表示(引述如下):相較於開腹手術,機器人手術可縮短住院天數。雖然初期投入成本高,但相較於傳統微創(鑰孔)手術,更多病患適用此微創途徑,具有帶來財務節省的潛力(引述完畢)。

  • da Vinci colorectal resections have been expanding rapidly over the past several quarters. The uptake has been driven by surgeons seeking to offer patients a less invasive alternative to open colorectal surgery. While laparoscopic colorectal surgery has been proven to be safe and effective and has for years been available within several leading institutions throughout the world, it has nonetheless remained largely under penetrated within the United States.

    達文西結直腸切除術在過去數個季度快速擴張。其採用主要由外科醫師推動,期望為病患提供較開腹結直腸手術侵入性更低的替代方案。儘管腹腔鏡結直腸手術已被證實安全有效,且多年來在全球多家領先機構均可施行,但在美國的滲透率仍然偏低。

  • In a recent edition of the Journal, Surgical Endoscopy, a study entitled Total Mesorectal Excision - a Comparison of Oncologic and Functional Results Between Robotic and Laparoscopic Rectal Surgery was published. The study, conducted in Rome, was based on 100 patients who had undergone minimally invasive anterior rectal resections with total mesorectal incisions or TME, 50 consecutive robotic rectal anterior resections with TME were compared to the first 50 consecutive laparoscopic rectal resections with TME. The authors made several comparisons, which included operating time, conversion rate, lymph node yields, circumferential margins, length of stay and sexual function scores.

    在近期一期《Surgical Endoscopy》期刊中,發表了一項名為〈全直腸系膜切除術(TME)—機器人與腹腔鏡直腸手術之腫瘤學與功能性結果比較〉的研究。該研究於羅馬進行,基於100名接受微創前位直腸切除並行全直腸系膜切除(TME)的病患;其中連續50例機器人直腸前位切除合併TME,與最初連續50例腹腔鏡直腸切除合併TME進行比較。作者進行了多項比較,包括手術時間、轉開腹率、淋巴結清除數、環周切緣、住院天數以及性功能評分。

  • They reported that the operative times were similar between the two groups with da Vinci holding only a slight advantage. Lymph node yields were greater using da Vinci, 16.5 versus 13.8. Conversions to open surgery were 0% within the da Vinci cohort as compared to 12% for the laparoscopic cohort. The circumferential margins, less than 2 millimeters, were zero using da Vinci as compared to 12% for the lap group.

    他們報告兩組手術時間相近,達文西僅略占優勢。使用達文西的淋巴結清除數較高,為16.5對13.8。達文西組轉為開腹手術的比例為0%,相較之下腹腔鏡組為12%。環周切緣小於2毫米的比例,達文西組為0%,而腹腔鏡組為12%。

  • In the author's conclusion, they wrote and I quote, robotic TME is oncologically safe and adequate for rectal cancer treatment, showing better results than laparoscopic TME in terms of circumferential margins, conversions and hospital length of stay, better recovery in voiding and sexual function is achieved with the robotic technique, close quote.

    在作者結論中,他們寫道(引述如下):機器人TME在直腸癌治療上於腫瘤學上安全且足夠;在環周切緣、轉開腹以及住院天數方面,結果優於腹腔鏡TME;採用機器人技術可在排尿與性功能方面獲得更佳的恢復(引述完畢)。

  • In the early days of an emerging procedure, single center comparative analysis with strong findings lays the foundation for larger and more comprehensive comparative studies. We would expect this trend to continue within the field of colon and rectal surgery.

    在新興術式的早期階段,單一中心的比較分析若有強而有力的發現,將為更大型且更全面的比較研究奠定基礎。我們預期此趨勢將在結腸與直腸外科領域持續。

  • This concludes my remarks, and I will now turn the time over to Calvin.

    以上為我的發言,接下來把時間交給Calvin。

  • Calvin Darling - Sr. Dir., Finance

    Calvin Darling - Sr. Dir., Finance

  • Thank you, Alex. I will be providing you with updated to our financial forecast for 2013, including procedures, revenues and other elements of the income statement on a GAAP basis. I will also provide estimates of significant non-cash expenses to provide you with visibility into our expected future cash flows. Starting with procedures, on our last call, we projected our full-year 2013 procedures to grow approximately 20% to 23% from the base of approximately 450,000 procedures performed in 2012. Now, based upon first-quarter procedure trends, we expect our full-year 2013 procedure growth to be in the lower end of that range.

    謝謝你,Alex。我將向各位提供我們2013年財務預測的更新,包括手術量、營收以及依GAAP編製的損益表其他項目。我也會提供重大非現金費用的估計,以便各位掌握我們預期的未來現金流。先從手術量開始,在上次電話會議中,我們預估2013年全年手術量將在2012年約45萬例的基礎上成長約20%至23%。現在,根據第一季手術量趨勢,我們預期2013年全年手術量成長將落在該區間的較低端。

  • Moving on to revenues, last quarter we forecasted full-year 2013 revenue growth of between 16% and 19%. Based upon favorable new instrument and accessory product sales and utilization, we now expect full-year 2013 revenue growth at the higher end of that range. Our first-quarter system ASP of $1.55 million was higher than we expected, reflecting a high proportion of dual-console configurations in the system mix.

    接著談營收,上季我們預測2013年全年營收成長介於16%至19%。基於新器械與配件產品銷售及使用率表現良好,我們目前預期2013年全年營收成長將落在該區間的較高端。我們第一季系統平均銷售價格(ASP)為155萬美元,高於我們預期,反映系統組合中雙主控台配置占比較高。

  • Going forward in 2013, we would expect our systems product mix and overall systems ASP to return towards historical 2012 levels.

    展望2013年後續期間,我們預期系統產品組合與整體系統ASP將回到接近2012年的歷史水準。

  • Now turning to operating income, we continue to expect full-year operating income to fall within a range of between 38% and 39% of net revenue. Our first-quarter operating margin of 41% reflected favorable system pricing and timing of operating expenses. In Q2 we would expect operating expenses to increase at least $15 million, reflecting higher variable compensation, prototype, headcount, stock compensation and legal expenses. We continue to expect 2013 stock compensation to total between $184 million and $192 million for the year. Timing of recognition should follow a quarterly pattern similar to 2012. Amortization of purchased intellectual property, which is mostly recorded as R&D expense, is still expected to come in between $28 million and $30 million in 2013.

    再來看營業利益,我們仍預期全年營業利益將落在淨營收的38%至39%區間。第一季41%的營業利益率反映有利的系統定價以及營業費用認列時點。在第二季,我們預期營業費用至少增加1,500萬美元,反映較高的變動薪酬、原型開發、人力編制、股票酬勞以及法律費用。我們仍預期2013年全年股票酬勞費用合計介於1.84億至1.92億美元。其認列時點應會呈現與2012年類似的季度型態。外購智慧財產權攤銷(多數列為研發費用)在2013年仍預期介於2,800萬至3,000萬美元。

  • We continue to expect other income to total between $18 million and $22 million in 2013. With regard to income tax, as Marshall described, our Q1 tax rate reflected the benefit related to the reinstatement of the 2012 R&D tax credit.

    我們仍預期2013年其他收益合計介於1,800萬至2,200萬美元。就所得稅而言,如Marshall所述,我們第一季稅率反映了2012年研發稅額抵減恢復適用所帶來的利益。

  • For the rest of this year, we continue to anticipate our tax rate to fall within a range of between 28% and 30% of pretax income. Our share count for calculating EPS in Q1 2013 was approximately 41.4 million shares. Going forward, our share count will depend upon the magnitude and timing of share buybacks. We will continue to be thoughtful in our execution of the $1.2 billion authorized by the Board for that purpose.

    在今年剩餘期間,我們仍預期稅率將落在稅前所得的28%至30%區間。用於計算2013年第一季每股盈餘(EPS)的流通股數約為4,140萬股。展望未來,我們的流通股數將取決於庫藏股回購的規模與時點。我們將持續審慎執行董事會為此目的核准的12億美元額度。

  • That concludes our prepared remarks. We will now open the call to your questions. Operator?

    以上為我們事先準備的發言。接下來我們將開放各位提問。接線員?

  • Operator

    Operator

  • (Operator instructions) Tycho Peterson, JPMorgan.

    (接線員指示) Tycho Peterson,摩根大通(JPMorgan)。

  • Evan Lodesen - Analyst

    Evan Lodesen - Analyst

  • It's [Evan Lodesen] for Tycho. I guess the first question was for Gary. Can you disaggregate the slowdown in benign dVH between the seasonal effects that you mentioned such as deductibles and then also the more coordinated efforts that you talked with regards to the robot, specifically?

    我是 Tycho 的 [Evan Lodesen]。我想第一個問題是問 Gary 的。你能否把良性 dVH 放緩的原因拆解一下:一部分是你提到的季節性因素(例如自付額),另一部分是你談到與機器人相關、較為協調一致的推動努力,尤其是這一塊?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • I think I heard the question, although there's a little bit of background noise on the phone. I think the question was, can we disaggregate the benign hysterectomy slowdown? I think there's a few things going on there. As we look at multiport benign hysterectomy in total, we think our market opportunity is really the open surgical market share. There's still more than 100,000 open benign hysterectomies being done in the US. We see three issues impacting benign hysterectomy. First, as we become a larger part of the market, the impact of seasonality plays an proportionally bigger role in our performance.

    我想我有聽到這個問題,雖然電話裡有一些背景雜音。我想問題是:我們能否把良性子宮切除術的放緩拆解開來?我認為這裡面有幾件事同時在發生。當我們看整體多孔式(multiport)的良性子宮切除術時,我們認為我們的市場機會主要來自開腹手術的市占。在美國仍有超過 100,000 例良性子宮切除術是以開腹方式進行。我們看到有三個議題在影響良性子宮切除術。第一,隨著我們在市場中占比變大,季節性因素對我們表現的影響會在比例上變得更大。

  • Said simply, when a new technique just a small part of the market, the number of unserved patients is sufficiently large that changes in the total number of patient admissions do not materially impact growth. However, as penetration increases, the sensitivity to total admissions increases with it.

    簡單說,當一項新技術在市場中只占很小一部分時,尚未被服務的病患數量足夠大,因此整體住院收治人數的變動不會對成長造成實質影響。然而,隨著滲透率提高,對總收治量的敏感度也會隨之提高。

  • Second, several large healthcare organizations are reporting a greater than expected decline in patient admissions in the first quarter. Given that benign hysterectomy is a large part of our procedure base, that will impact us as well.

    第二,有幾家大型醫療體系回報第一季病患收治量的下滑幅度高於預期。鑑於良性子宮切除術在我們的手術基礎中占比很大,這也會影響到我們。

  • Third, negative press has some hard-to-measure impact on benign hysterectomy, although it doesn't appear to be large. It's also probably not zero.

    第三,負面新聞對良性子宮切除術有一些難以衡量的影響,雖然看起來不大。但可能也不是零。

  • Evan Lodesen - Analyst

    Evan Lodesen - Analyst

  • And then, the second question -- you mentioned international procedure growth was about 14%. Could you help us think about what the growth is in Europe and trends there that you have seen recently?

    然後第二個問題——你提到國際手術量成長大約是 14%。你能否協助我們理解歐洲的成長情況,以及你最近看到的趨勢?

  • Aleks Cukic - VP, Strategic Planning

    Aleks Cukic - VP, Strategic Planning

  • Just numerically, the 14% would be higher on the Asia and rest of world markets and a bit lower on the European side.

    就數字而言,14% 在亞洲及其他世界市場會更高一些,而在歐洲那邊會低一些。

  • Operator

    Operator

  • Benjamin Andrew with William Blair.

    William Blair 的 Benjamin Andrew。

  • Benjamin Andrew - Analyst

    Benjamin Andrew - Analyst

  • Gary, talk a little bit about the guidance of 20% to 23% and targeting the low end of that range. What does it take for you to hit that 20%? Does it require a stabilization in benign dVH and, again, continued stabilization of prostatectomy? And just maybe walk through how you get to that 20% because we're struggling a little bit as we try to plug in the number for Q1 to get there.

    Gary,談談 20% 到 23% 的指引,以及你們把目標放在區間低端的原因。要達到 20% 需要什麼條件?是否需要良性 dVH 穩定下來,並且前列腺切除術也持續穩定?也請你大概帶我們走一遍你們如何達到 20%,因為我們在把第一季的數字代入後要推到那個目標時有點卡住。

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • A couple of things, and then Calvin may help you a little bit with that as well. But as we look out, we have seen three quarters in a row with prostatectomy where it's finding its footing with regard to [aduwes] so we are assuming that that trend stays about the same as we go through. General surgery has shown real strength.

    有幾件事,Calvin 也可能會在這方面幫你補充一些。但就我們往前看,前列腺切除術已經連續三個季度在 [aduwes] 方面逐步站穩腳步,因此我們假設這個趨勢在接下來大致會維持不變。一般外科展現出真正的強勁動能。

  • On benign gynecology, I want to make sure we are separating out gynecologic procedures from just hysterectomy. There's more in benign gynecology than just hysterectomy; there's myomectomy and sacrocolpopexy, both of which were meeting our expectations in this quarter. The quarter is a little bit hard to interpret just because of the number of operating days, and there's a little bit of ambiguity as to how many there were in terms of how the holiday played.

    在良性婦科方面,我想確保我們把婦科手術與單純的子宮切除術區分開來。良性婦科不只有子宮切除術;還有子宮肌瘤切除術(myomectomy)和薦骨陰道固定術(sacrocolpopexy),這兩項在本季都符合我們的預期。本季有點難解讀,主要是因為手術日天數的因素,而且假期如何落點導致實際天數有些模糊。

  • And we will have to see a little bit. Impossible to predict the future perfectly. We look out and think that our guidance at the low end makes sense, given those three factors together.

    我們還需要再觀察一下。不可能完美預測未來。我們往前看,認為在這三個因素合併之下,把指引放在低端是合理的。

  • Calvin Darling - Sr. Dir., Finance

    Calvin Darling - Sr. Dir., Finance

  • As we look at our guidance, there are a lot of moving parts, more and more, as you realize. But the key areas of growth are the same as they were entering the year, specifically the number of new procedures coming from US general surgery, US gynecology and international PPP are going to be still the largest areas of growth. As Gary said, based upon customer insurgent feedback we have not seen a major impact on the benign dVH procedure demand, although we cannot really predict where that may hit in the future.

    當我們看我們的指引時,如你所知,變動因素很多,而且越來越多。但成長的關鍵領域與年初進入本年度時相同,特別是:美國一般外科、美國婦科帶來的新手術量,以及國際 PPP,仍將是最大的成長來源。如 Gary 所說,根據客戶一線回饋,我們尚未看到良性 dVH 手術需求受到重大影響,儘管我們無法真正預測未來是否會受到衝擊。

  • We expect seasonality to play through and we will benefit later in the year on some of these things as well. And we do forecast that dVP has bottomed out. So I think that's --

    我們預期季節性因素會持續發酵,而我們也會在今年稍晚從其中一些因素中受益。另外我們也預測 dVP 已經觸底。所以我想那就是——

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • Having said that, nobody has a crystal ball. And we will take it one quarter at a time.

    話雖如此,沒有人有水晶球。我們會一季一季地來。

  • Benjamin Andrew - Analyst

    Benjamin Andrew - Analyst

  • Two more quick questions, Gary. Are you hearing additional chatter or disturbing chatter from either surgeons or hospitals questioning the safety and perhaps the efficacy of the system? I know that's really hard to quantify, but does it feel different now than it did a month ago? And were the trends in the quarter something that got your attention?

    再兩個快問,Gary。你是否聽到更多的傳言或令人不安的聲音,來自外科醫師或醫院,質疑系統的安全性,甚至可能是有效性?我知道這很難量化,但現在的感覺和一個月前相比有不同嗎?而本季的趨勢是否引起你們注意?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • It's interesting. With regard to surgeon feedback on use of our device, the safety and stability of it, surgeons are the ones who are absolutely closest to it. They work with it every day. We have seen very little change in their viewpoint in terms of people who actually know the device. And likewise, that's true with hospitals who are our customers.

    這很有意思。就外科醫師對我們設備使用的回饋、以及其安全性與穩定性而言,外科醫師是最貼近的人。他們每天都在使用。就真正了解這個設備的人而言,我們看到他們的觀點幾乎沒有改變。同樣地,對作為我們客戶的醫院也是如此。

  • These kinds of questions do come up in conversations. They come up in conversation with sales teams. But we have not seen a substantial change in the nature of that conversation, say, over the last few weeks of the quarter as we go through it.

    這類問題確實會在對話中出現。也會在與銷售團隊的對話中出現。但我們並未看到這些對話的性質有實質改變,例如在本季後幾週的期間。

  • Benjamin Andrew - Analyst

    Benjamin Andrew - Analyst

  • Okay, and then, finally, you mentioned something intriguing about SG&A spending popping up in the second quarter. I thought I heard prototyping in the middle of that list. Can you describe that at all?

    好的,最後,你提到第二季 SG&A 支出會跳升,這點很耐人尋味。我想我有聽到你在那串項目中提到原型製作(prototyping)。你能否描述一下那是什麼?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • Yes. We have always said prototypes are going to be lumpy. Right? And I think if you look sequentially at operating expenses, they decline from Q4 to Q1 and it was relatively light in the areas that Marshall mentioned in his script. And I think you are going to see a pickup in the items that I mentioned including prototypes.

    可以。我們一直都說原型製作的費用會比較不均勻、起伏較大。對吧?而且我想如果你按季看營運費用,從第四季到第一季是下降的,而且在 Marshall 講稿中提到的那些領域相對偏輕。我想你會看到我提到的那些項目回升,包括原型製作。

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • Then, you had asked the question, just to follow up, on surgeon's view and surgeon's commentary on it. I will tell you one surgeon's comments to me with regard to some of the criticism that has been up there. He came back and said, hey, open surgery hasn't gotten any better for patients and laparoscopy hasn't gotten any easier for surgeons. And I think that's true.

    另外,你剛才問到外科醫師的看法與評論,我補充追問一下。我可以跟你分享一位外科醫師對我談到近期一些批評時的說法。他回我說,嘿,開腹手術對病患並沒有變得更好,而腹腔鏡對外科醫師也沒有變得更容易。我認為這是真的。

  • Benjamin Andrew - Analyst

    Benjamin Andrew - Analyst

  • We have definitely heard the same thing. Thank you.

    我們確實也聽到同樣的說法。謝謝。

  • Operator

    Operator

  • Lennox Ketner, Bank of America.

    美國銀行的 Lennox Ketner。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Just a few questions -- first, I'm sorry if I missed it. I think you said that dVP was down about 11% year-over-year. But last quarter you had provided, I think, the overall growth rates for both general surgery and gynecology as well. Is that something you would be willing to break out this time?

    幾個問題——首先,如果我漏聽了先抱歉。我想你說 dVP 年對年大約下滑 11%。但上一季你們也提供了我記得一般外科與婦科的整體成長率。這次你們願意也把這兩項拆開來提供嗎?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • We do that on an annual basis and not quarterly.

    我們是以年度為基礎來做,而不是按季度。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Okay, had to try. And then on the stapler, I was a little surprised to hear you say that people shouldn't be expecting any meaningful contribution from that product this year, just given that it's been on the market for six months or so now or, sorry, been approved, at least, for six months now. Could you maybe just give us a little more color in terms of why the launch of that product is expected to be so measured? Are there additional features that need to be added to the stapler to make it more effective? Or is it really just wanted to make sure that the initial customer experiences are good? If you could maybe just give people a little bit more of an explanation as to why that launch is expected to take so long or why it's expected to take so long assuming meaningful contribution?

    好吧,總得試試看。接著談到縫合器(stapler),我有點驚訝聽到你說,今年大家不應該期待這個產品會有任何具實質意義的貢獻,畢竟它上市大概已經六個月左右了,或者抱歉,至少獲准也已經六個月了。你能否再多提供一些背景,說明為什麼這個產品的上市推進預期會這麼審慎、循序漸進?是否還需要在縫合器上增加額外功能,才能讓它更有效?或者其實只是想確保初期客戶的使用體驗良好?如果可以的話,能否再多解釋一下,為什麼這次上市預期會花這麼久,或在假設要有具實質意義的貢獻之下,為什麼預期會需要這麼長時間?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • For starters, while we had the approval last year, the first clinical cases are -- happened in this quarter. And really, the reason for it is twofold. One is we want to have outstanding first customer experiences with it. So far, we have.

    首先,雖然我們去年就取得核准,但第一批臨床案例是在本季才發生。而真正的原因有兩個。其一是我們希望第一批客戶的使用體驗非常出色。到目前為止,我們做到了。

  • The second thing is the supply chain for the surgical stapler is a long one. It's a full system. It has electronics in it, software in it, motor packs and single-use sterilizable products.

    第二點是,手術縫合器的供應鏈很長。它是一個完整系統。裡面有電子元件、有軟體、有馬達模組,以及一次性可滅菌的產品。

  • So, we want to make sure that that supply chain is exceptionally stable and ready. Coming as we move to scale. And it's really working those two things in parallel to make sure we get a great result.

    因此,我們要確保供應鏈極其穩定並且準備就緒,以便在我們擴大規模時能順利供應。我們就是同時並行推進這兩件事,確保能取得很好的結果。

  • Stapling is a subtle product. There are a lot of things about it in terms of both its manufacture and its use that you want to make sure you get right. And so we will be doing that. And as we start to see that stability, then we will start to ramp the release.

    縫合是一個很細緻的產品。無論在製造或使用上,都有很多細節需要確保做到位。所以我們會把這些做好。當我們開始看到那種穩定性之後,就會開始加速放量、擴大釋出。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Okay. But from a feature standpoint, you feel confident that the version that you have now has all the features that it needs to ultimately be successful?

    了解。但就功能面而言,你有信心目前這個版本已具備最終成功所需的所有功能嗎?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • It does. Now, remember we have talked in the past that we are focusing this first stapler on the colorectal market. And so the size of the staple loads both in terms of their length and the size of the staples that go in these little cartridges are optimized for colorectal.

    是的。另外請記得,我們過去談過,第一代縫合器我們聚焦在大腸直腸(colorectal)市場。因此,釘匣(staple loads)的尺寸——包括長度,以及裝在這些小匣盒裡的釘腳尺寸——都是針對大腸直腸手術做最佳化。

  • In time we will start to add different sized cartridges and different leg length staples to allow us to do other things. So this is really just the first step in a multistep process. But it's not the lack of a particular feature for colorectal that has us moving at the pace we are moving.

    未來我們會逐步加入不同尺寸的匣盒,以及不同釘腳長度的釘子,讓我們能做其他類型的手術。所以這其實只是多步驟流程的第一步。但我們目前的推進速度,並不是因為在大腸直腸用途上缺少某個特定功能。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Okay, that's helpful. And then last one, just on the buyback authorization -- I think it was obviously a much larger authorization that you guys have done in the past. I think people are happy to see, but how should we think about the timing of that going forward? In the past, [US] has been pretty measured buybacks over time. Should we expect this one to occur any more quickly than the others or is it going to continue to be at the same pace as the others by being a larger overall authorization?

    好,這很有幫助。最後一個問題,關於庫藏股回購授權——我想這次的授權規模顯然比你們過去做過的都大。我想大家樂見其成,但我們應該如何看待未來執行的時點與節奏?過去你們的回購一直是隨時間相對審慎、循序漸進地進行。這次是否應該預期會比以往更快執行,還是會維持與以往相同的節奏,只是整體授權額度更大?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • I think you have somewhat characterized how we have approached it. We have not been mechanical; we have been very thoughtful about what we have done and we will continue to be thoughtful. So you shouldn't look for any particular standard pattern, if you will. We will look for the right opportunities to buy back, over time.

    我想你對我們做法的描述大致正確。我們不是機械式地執行;我們一直非常審慎地思考我們所做的事,未來也會持續審慎。所以你不應該期待會有任何特定的固定模式。我們會隨時間推進,尋找合適的回購機會。

  • Operator

    Operator

  • David Roman, Goldman Sachs.

    David Roman,高盛。

  • David Roman - Analyst

    David Roman - Analyst

  • I was hoping you could talk a little bit more about any efforts you are undertaking or look to undertake to address the weakness in dVH. Obviously, the seasonal piece in macro dynamics are what they are. But maybe any sort of impact you have had from the recent noise in the marketplace, what is your plan to start to stem that and then how long do you think it might take before we start to see some positive return from those efforts?

    我希望你能再多談一點,你們正在進行或計畫進行哪些努力,以因應 dVH 的疲弱。顯然,總體環境中的季節性因素就是那樣。但也許可以談談近期市場雜音對你們造成的任何影響、你們打算如何開始遏止這種情況,以及你認為要多久我們才會開始看到這些努力帶來一些正向回報?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • On the first comment of what do we think there is, in terms of opportunity in benign dVH, first of all we look out and say open procedures that are still being done through a laparotomy are great opportunities for us. We look around the country to see where those are and our ability to serve those patients. That's our primary opportunity.

    針對第一個問題,也就是我們認為在良性 dVH 方面有哪些機會,首先我們往外看,仍然有許多透過剖腹(laparotomy)進行的開腹手術,對我們而言是很好的機會。我們會在全國各地觀察這些手術在哪裡發生,以及我們服務這些病患的能力。這是我們的主要機會。

  • You implied in your discussion that the negative press is having a fair impact in this. It's not clear that that's true. Right now, separating out how much of this is seasonality, how much is just a total inpatient admission and how much is specific to intuitive is actually a hard thing to tease apart.

    你在討論中暗示負面報導對此有相當影響。但目前並不清楚是否真是如此。就現在而言,要把其中多少是季節性因素、多少只是整體住院收治量(inpatient admission)的變化、以及多少是直覺外科(Intuitive)特有的因素區分開來,其實很難釐清。

  • Having said that, I think the strength of da Vinci surgery has been in its clinical outcomes. And so that's where we start, relative to open surgery both in the publications and in the education of our sales team and the interaction with hospitals, it's that set of data. And so we have done and we will continue to do that in terms of supplying them the data and resources they need to approach those patients.

    話雖如此,我認為達文西手術的強項一直在於其臨床結果。因此我們就從這裡著手:相較於開腹手術,無論是在文獻發表、銷售團隊教育,或與醫院互動上,核心都是那一組數據。所以我們已經在做、也會持續做的,就是提供他們所需的數據與資源,讓他們能去接觸那些病患。

  • Over time, as we go through the year, we have Single-Site hysterectomy, which is really a little bit different marketplace. And that's, again, not looking so much at open procedures but looking at those patients who would rather have a single incision than multiport. And that, as we get to the close of the year, might just start to give us an opportunity to access a different group of patients.

    隨著時間推進、進入今年後續,我們還有單孔子宮切除術(Single-Site hysterectomy),那其實是稍微不同的市場。這同樣不是那麼著重於開腹手術,而是著眼於那些寧可選擇單一切口、而非多孔(multiport)切口的病患。而當我們接近年底時,這可能會開始給我們一個機會,去觸及另一群不同的病患。

  • David Roman - Analyst

    David Roman - Analyst

  • That's helpful. And I know a lot of the questions on this call regarding market recent noise or marketplace concerns have been focused on gynecology. But is it fair to say that hasn't trickled into the other parts of your business or the newer categories like general surgery that continues to be fairly robust, in your ability to attract new users, train new users? Any change in the size of your training classes, interest level? Any other metrics that you could help us to gauge this looming question around noise versus reality?

    這很有幫助。我知道這通電話中,很多關於近期市場雜音或市場疑慮的問題都聚焦在婦科。但是否可以說,這些情況並沒有蔓延到你們業務的其他部分,或像一般外科等較新的類別;你們在吸引新使用者、訓練新使用者方面仍相當強勁?你們的訓練課程班級規模、興趣程度有任何變化嗎?還有沒有其他指標可以幫助我們衡量這個「雜音 vs. 現實」的懸而未決問題?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • We have not seen a change in the desire for people to be trained. We haven't seen anything that I can point to in the general surgery marketplace that would indicate a real impact.

    我們沒有看到人們想接受訓練的意願有任何改變。在一般外科市場上,我也沒有看到任何我能指出、足以顯示有實質影響的跡象。

  • Aleks Cukic - VP, Strategic Planning

    Aleks Cukic - VP, Strategic Planning

  • Yes. And again, I think evidence of that, that we have that helps us make that statement, are the actual procedure numbers, the number of people who are accessing proctors and training. And just as a level set, GYN, if you look at things like say, (inaudible) myomectomy and endometriosis resection, GYN is a -- and hysterectomy for malignant conditions, it is a very robust category. And while dVH benign is certainly the largest individual segment of that category, as we look out over all of GYN, we remain very encouraged.

    是的。再者,我認為能支持我們做出上述判斷的證據,是實際的手術量數據、使用導師(proctors)與訓練的人數。另外先做個基準說明:婦科(GYN)如果你看例如(聽不清)肌瘤切除(myomectomy)與子宮內膜異位切除(endometriosis resection),以及惡性適應症的子宮切除術,婦科是一個——非常強勁的類別。而雖然良性 dVH 的確是該類別中最大的單一分項,但當我們放眼整個婦科領域時,我們仍然非常受到鼓舞。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay. And maybe last question, just to follow up on the share repurchase authorization -- in the past, I think you guys have used share repurchase to offset the impact of options being exercised and it has been not a top use of cash but something that you have done to manage options, dilution. Is anything different or is there a prioritization to think about this $1 billion authorization, or it's just the cash balance has gotten to where it is, the stock price is where it is, so you need more to offset the impact of options exercised?

    好的。那也許最後一個問題,想追問一下股票回購授權——過去我想你們曾用股票回購來抵銷員工期權被行使的影響,這並不是現金的首要用途,但你們確實用它來管理期權與稀釋。這次有什麼不同嗎?對這項10億美元授權是否有優先順序的考量?還是只是因為現金餘額到了目前的水位、股價也在目前的水位,所以你們需要更多回購來抵銷期權行使的影響?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • I think, number one, is the authorization reflected confidence in the business. But I think that it's also intended to be a return to shareholders. We are talking about $1 billion. That more than offsets any stock option dilution that we create through here.

    我想第一點,這項授權反映了我們對業務的信心。但我也認為,這同時是要回饋股東。我們談的是10億美元。這個金額足以、而且遠遠超過我們因期權而產生的任何股票稀釋。

  • Operator

    Operator

  • Lawrence Keusch.

    Lawrence Keusch。

  • Lawrence Keusch - Analyst

    Lawrence Keusch - Analyst

  • Gary, there has been obviously a lot of discussion focused on procedures and the impact from the critics over the last several months. But I'm wondering if we can perhaps shift toward system sales, obviously quite strong this quarter. But I'm wondering if you are seeing anything change in the selling cycle or there have been some speculation that hospitals may hold back on purchasing while there is all this noise out there. So any color would be helpful.

    Gary,過去幾個月顯然有很多討論聚焦在流程以及批評者所帶來的影響。但我想把話題轉到系統銷售,本季顯然相當強勁。不過我想問的是,你們是否看到銷售週期有任何變化?外界也有一些揣測,認為在這些雜音之下,醫院可能會暫緩採購。所以若能提供一些看法會很有幫助。

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • All I can speak to is the first quarter, and looking at the first quarter we haven't seen any meaningful impact of negative press on capital sales. In fact, the capital side was pretty strong, as we mentioned, not only in systems as a whole but in the attachment of some of the products we've added to SI. So console sales, simulator sales, Firefly demand have continued to be strong.

    我只能就第一季來談;從第一季來看,我們沒有看到負面媒體對資本設備銷售造成任何實質影響。事實上,如我們提到的,資本端表現相當強勁,不僅是整體系統,還包括我們新增到SI上的一些產品的搭售/附加。因此,主機台(console)銷售、模擬器銷售,以及Firefly的需求都持續強勁。

  • Again, don't have a crystal ball as to what happens in the future. But so far the conversations have been pretty straightforward.

    再次強調,我沒有水晶球能預測未來會發生什麼。但到目前為止,對話都相當直接明確。

  • Lawrence Keusch - Analyst

    Lawrence Keusch - Analyst

  • Okay, great. And then this also has come up over the last several calls. You have expressed some need to work on the European organization. So I'm just curious, kind of take your temperature a little bit on where we are in that process.

    好的,很棒。另外,這也在過去幾次電話會議中被提到。你們曾表示需要改善歐洲組織。所以我想了解一下目前進展到哪個階段,算是幫大家掌握一下現況。

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • I think that we have been making good progress. I think that it's been measured but we have been adding resources in a few places. Some of it has been leadership resources, some of it has been people in the sales force, experienced people in the sales force. And some of it is in areas such as regulatory and reimbursement. We have made some great hires there. They are integrating well. And as we have said in the past, this is something that will happen over quarters, not over days. But we are pleased with our progress.

    我認為我們已經取得不錯的進展。我想這是循序漸進的,但我們確實在幾個地方增加了資源。其中一部分是領導層資源,一部分是銷售團隊的人員,尤其是有經驗的銷售人員。另外一部分是在法規與給付(reimbursement)等領域。我們在那裡做了很棒的招募。他們也整合得很好。而且如同我們過去所說,這會是以季度為單位推進,而不是幾天內就完成。但我們對目前的進展感到滿意。

  • Lawrence Keusch - Analyst

    Lawrence Keusch - Analyst

  • Okay, and then lastly just on the uses of cash, obviously share repurchase remains out there. But what are the latest thoughts around potentially using cash for some M&A opportunities?

    好的,最後再問一下現金用途。顯然股票回購仍在規劃中。

  • Calvin Darling - Sr. Dir., Finance

    Calvin Darling - Sr. Dir., Finance

  • I think our eyes are always open for opportunities for a few things. And some of it has been, as you know, in the past looking for technologies that we think fit really well with robotic surgery and advancing the ability of surgeons in the system to do more. We continue to be looking for and able to acquire those things that we think make a difference.

    我想我們一直都在留意幾類機會。其中一部分,如你所知,我們過去一直在尋找我們認為非常契合機器人手術、並能提升外科醫師在系統上能力、讓他們能做更多事情的技術。我們仍持續尋找並在有能力時收購那些我們認為能帶來差異的項目。

  • We also think that investments in markets not in the United States are really important. You've seen us do that in the past and we continue to do so in terms of investing into existing organizational frameworks in Japan and in Korea and also positioning ourselves for success in other markets OUS. And having cash helps us do that as well.

    我們也認為,對美國以外市場的投資非常重要。你們過去也看到我們這麼做,我們會持續投資於日本與韓國既有的組織架構,同時也為在其他美國以外(OUS)市場的成功做好布局。而持有現金也能幫助我們做到這些。

  • Lawrence Keusch - Analyst

    Lawrence Keusch - Analyst

  • Okay, terrific, thank you.

    好的,非常好,謝謝。

  • Operator

    Operator

  • David Lewis, Morgan Stanley.

    David Lewis,Morgan Stanley。

  • Unidentified Participant

    Unidentified Participant

  • Hello, this is actually John in for David. So we had a few questions, one just while procedures were a little bit slower than expected, instrument revenue is still strong. And I guess that was more related to the revenue per procedure being higher. And I was wondering if you could maybe break that out and how much of that was really the stocking versus how much of that was some more advanced tools?

    你好,我其實是代替David的John。我們有幾個問題:首先,雖然手術量(procedures)比預期稍慢,但器械收入仍然強勁。我猜這更多是因為每例手術收入(revenue per procedure)較高。我想請你們拆解一下:其中有多少真的是備貨(stocking),又有多少來自更進階的工具?

  • You mentioned thoughts on the system ASP as being normalized down a bit. Any thoughts to where revenue per procedure should go throughout the year?

    你們提到系統ASP似乎已回到較正常水準、略為下修。那對於全年每例手術收入的走勢,你們有什麼看法?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • We have actually seen a bit of an uptick in what we call the base. So if you parse out stocking orders associated with new system purchases, we see a little uptick in the base. And that reflects the new products. So that reflects usage of Firefly, usage of vessel sealing. And I think it was also benefited -- the quarter was also benefited by the timing of purchases of INA through distributors and other customers, where they are entering their new fiscal year, so they may have bought more.

    我們其實看到我們所稱的「基礎」(base)有些微上升。也就是說,如果把與新系統採購相關的備貨訂單拆開來看,我們看到基礎有些微上升。而這反映了新產品。也就是反映Firefly的使用、血管封合(vessel sealing)的使用。我也認為本季還受惠於INA透過經銷商與其他客戶的採購時點;他們進入新的會計年度,因此可能買得更多。

  • So I think it was a little bit higher than maybe we would expect going forward. But it's definitely being benefited by the new product.

    所以我認為這可能比我們對未來的預期稍高一些。但它確實受惠於新產品。

  • Aleks Cukic - VP, Strategic Planning

    Aleks Cukic - VP, Strategic Planning

  • Yes, and we have always talked is a lot of moving parts in this overall instrument accessory per procedure. We have talked in the past about a national trend downward as the impact of stocking orders becomes less on a larger installed base and procedure mix, moving towards a simpler mix, may move it downwards. But now that we are seeing the impact of the new products, even beyond the initial stocking of the new products as we have talked before, we are talking about utilization of products like the Vessel Sealer and the Firefly in procedures, which -- getting those procedures utilized and those products used in procedures it is allowing us really to capture a larger portion of the hospital's procedures spend through the da Vinci platform.

    是的,而且我們一直都在談,整體的每例手術器械與配件(instrument accessory per procedure)有很多變動因素。我們過去談過,隨著裝機量變大、備貨訂單的影響降低,以及手術組合(procedure mix)往較簡單的組合移動,整體可能呈現全國性下滑趨勢。但現在我們看到新產品的影響,甚至不只是如我們先前所說的新產品初期備貨;我們談的是像Vessel Sealer與Firefly這類產品在手術中的使用率——讓這些手術採用、讓這些產品在手術中被使用,確實使我們能透過達文西(da Vinci)平台,擷取醫院手術耗材支出中更大的一部分。

  • And so directionally, we probably see that winning the day, at least for the balance of this year.

    因此就方向性而言,我們可能會看到這個因素占上風,至少在今年剩餘期間是如此。

  • Unidentified Participant

    Unidentified Participant

  • Thank you, very helpful. And then a quick follow-up on Single-Site chole. First I was more curious, too, if you could break out how much Single-Site chole is out of all choles and then also just seeing kits increase each year on the Single-Site side and I was wondering if you could maybe discuss how much of those are repeat buyers, how much of those are new adopters and just what you've seen there.

    謝謝,很有幫助。接著快速追問一下Single-Site膽囊切除(chole)。第一,我比較好奇你們能否拆解一下:在所有膽囊切除中,Single-Site占比大概多少?另外,我們也看到Single-Site這邊的套件(kits)每年都在增加,我想請你們談談其中有多少是重複購買者、有多少是新採用者,以及你們觀察到的情況。

  • Aleks Cukic - VP, Strategic Planning

    Aleks Cukic - VP, Strategic Planning

  • Yes. At this point in time the Single-Site chole -- it is really moving from an initial introduction in some key element of our business here, a lot more mature status. We have talked about the number of customers who have bought Single-Site products. We may move away from that, I think, as it becomes part of the norm. The portion that Single-Site versus multiport -- that's always transitioning. As most people are aware, the multiport side is generally part of the training pathway to move towards single port.

    是的。就目前而言,Single-Site膽囊切除——它正從初期導入、在我們業務中的某些關鍵要素,逐步走向更成熟的階段。我們曾談過購買Single-Site產品的客戶數。我想隨著它成為常態的一部分,我們可能會逐步不再強調那個指標。至於Single-Site相對於多孔(multiport)的占比——那一直在轉換中。如大多數人所知,多孔通常是朝向單孔(single port)訓練路徑的一部分。

  • But I think the multiport side is really just that; it's an avenue to move towards the ultimate destination of the single port. So it's probably not as important at any point in time how many of those are.

    但我認為多孔端就是那樣;它是一條通往最終目標——單孔——的途徑。所以在任何時間點,多孔到底占多少可能就沒那麼重要。

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • Just a qualitative remark on the reorder rate. We have been watching it and we have been pleased so far. Reorder rate has been positive for us.

    關於再訂購率的一點定性評論。我們一直在觀察,而且到目前為止我們很滿意。再訂購率對我們而言一直是正面的。

  • Operator

    Operator

  • Amit Hazan, SunTrust.

    Amit Hazan,SunTrust。

  • Amit Hazan - Analyst

    Amit Hazan - Analyst

  • I thought maybe I would first ask about Single-Site for dVH. I think I was a little bit surprised in thinking back in your interaction with Single-Site for chole and what that did in 2012, essentially its first year. In your comments that you thought it might not have much of an impact this year, so I thought maybe you could explain the differences between the rollout here versus the rollout for chole is and why it's going to take a little bit longer.

    我想我可能先問一下 dVH 的單一切口(Single-Site)。回想你們在 2012 年(基本上是第一年)推出用於膽囊切除(chole)的 Single-Site,以及當時帶來的影響,我有點意外。你們評論說今年可能不會有太大影響,所以我想也許你們可以解釋一下,這次的推廣與當時 chole 的推廣有何不同,以及為什麼這次會需要更長時間。

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • Well, again, as you know, we are pretty measured in our approach with all of these various procedures. And I think when you look at single incision hysterectomy, you are looking at products that are required to be made, which we are doing and we know how to do that. And then you are looking at really understanding -- the physicians are looking at really understanding procedure choreography. How do I do this? How do I do that? How do I close the cuff? How do I take the adnexa, etc.?

    嗯,再次如你所知,我們在所有這些不同手術項目上的做法都相當審慎、循序漸進。我想當你看單一切口子宮切除術時,你會看到需要製造的產品,我們正在做,而且我們知道怎麼做。接著你會看到真正需要理解的是——醫師需要真正理解手術的「流程編排」。我該怎麼做這個?我該怎麼做那個?我該如何縫合陰道殘端(cuff)?我該如何處理附件(adnexa)等等?

  • And so, it's difficult to try to assign a reasonable timeline to how the choreography will go, in addition to the general issues of manufacturing new products, getting the supply chain down, etc. So we are being pretty cautious about that.

    因此,除了製造新產品、把供應鏈等一般性問題理順之外,要為這套流程編排的進展指定一個合理的時間表其實很困難。所以我們在這方面相當謹慎。

  • Now, if it turns out that that changes in time, we will certainly let you know. But I think there are a number of surveys that people have done and we have done ourselves where there's a real excitement for it from a customer. And so, we just want to make sure you take this into consideration and not work that into your expectations because it's really too early to call.

    如果隨著時間推移情況有所改變,我們當然會告訴你。但我認為有不少人做過的調查,以及我們自己做的調查,都顯示客戶端對此確實很興奮。因此,我們只是希望你把這點納入考量,不要把它納入你的預期之中,因為現在下結論還太早。

  • Amit Hazan - Analyst

    Amit Hazan - Analyst

  • Okay. And then on the systems side, just the comment you made about system mix in ASPs maybe not holding through the whole year -- I'm just wondering if that's more product mix related, or is that geography related. And if it's on the product side, just specifically what you are thinking in terms of the products that might not be there later in the year that you have been selling.

    好的。另外在系統方面,你提到系統組合對 ASP 的影響可能無法維持整年——我想知道這比較是產品組合的因素,還是地理區域的因素。如果是產品端的因素,你具體在想的是哪些產品可能在今年稍晚不會像現在這樣持續銷售?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • Yes, it's primarily product mix. We had 48 of the 164 units were dual console systems in the first quarter. That's by far and away the highest proportion that we've had. We'd see that attach rate returning to more historical levels. And as such, the ASP would be less than we saw here in the first quarter, maybe more in line with what we saw throughout 2012.

    是的,主要是產品組合。第一季 164 台中有 48 台是雙控制台(dual console)系統。這是我們迄今為止最高的占比。我們預期這個搭載率會回到較符合歷史水準的水位。因此,ASP 會低於第一季看到的水準,可能更接近 2012 年全年的水準。

  • Amit Hazan - Analyst

    Amit Hazan - Analyst

  • Okay, and then last one for me -- I realize with regard to the FDA MedSun Survey, I guess it was only nine people. So maybe it's not even a survey or definitely not a government probe, as maybe some would call it. But have you guys talked to any of the doctors involved in that kind of in career? Do you know anything about the report that might be coming out with what you might be anticipating?

    好的,最後一個問題——我知道關於 FDA 的 MedSun 調查,我想只有 9 個人。所以也許那甚至不算調查,或至少肯定不是某些人所稱的政府調查行動。但你們是否和參與其中的醫師談過,了解他們的情況?你們是否知道可能會出來的報告內容,或你們預期會是什麼?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • As far as we know, it was a confidentially run survey. And so we have no -- nothing to share on that front.

    就我們所知,那是一項以保密方式進行的調查。因此我們在這方面沒有——沒有任何可以分享的內容。

  • We have time for one more question.

    我們還有時間再問一個問題。

  • Operator

    Operator

  • Rick Wise, Stifel Nicolaus.

    Rick Wise,Stifel Nicolaus。

  • Mira Slava - Analyst

    Mira Slava - Analyst

  • Hi, it's actually [Mira Slava] for Rick today. Let me start with asking a question on Japan. I could not help but notice a significant number of systems you have placed there this quarter. It coincided with the SI approval in Japan. Was the SI what you needed to help unlock this market to some extent? And related to that, should we expect this kind of rate to continue, or do you view this as an anomaly, as you launch the SI?

    嗨,今天其實是我 [Mira Slava] 代替 Rick。我先從日本的問題開始。我注意到你們本季在日本佈署了相當多的系統。這與 SI 在日本獲准同時發生。SI 是否是在某種程度上幫助你們打開這個市場所需要的關鍵?另外,這樣的速度是否會持續,還是你們認為這只是推出 SI 時的異常現象?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • I think that they were happy to get SI approval and I think it has been well received. I think that there's some amount of early excitement having to do with SI. Long-term, as you look at that market, procedure reimbursement is going to be the thing that is a long and sustained growth path. So I think system sales in Japan are going to be lumpy until additional procedures are reimbursed. And that's something that we are working with surgical societies on, on supporting them and helping them complete that activity.

    我想他們很高興 SI 獲准,而且我認為市場反應良好。我想確實有一部分早期的熱度與 SI 有關。長期來看,當你看那個市場時,手術項目的健保給付(reimbursement)將會是帶來長期且持續成長路徑的關鍵。因此,在更多手術項目獲得給付之前,日本的系統銷售會呈現不均勻、起伏(lumpy)。而這也是我們正與外科醫學會合作的方向,支持他們並協助他們完成相關工作。

  • One last question, please.

    請再一個最後的問題。

  • Mira Slava - Analyst

    Mira Slava - Analyst

  • And going back to just that, quote, concerted effort by the critics of surgery, I was wondering if you have any plans to highlight some of your data on the outcomes and perhaps the economics of your procedures. And it goes back to what was asked earlier, but maybe if I could ask it a little bit differently, has your conversation with your customers changed in any way as a result of the negative press?

    回到你提到的、引述所謂外科手術批評者的「有組織的努力」,我想知道你們是否有計畫強調一些你們在療效結果以及或許在經濟性方面的數據。這也呼應先前有人問過的問題,但我想換個方式問:在負面報導之後,你們與客戶的對話是否有任何改變?

  • Gary Guthart - Pres and CEO

    Gary Guthart - Pres and CEO

  • There's two questions in there. On the first one, do we have plans to share our data, yes, we do. And we have been and we will continue to do so.

    這裡面有兩個問題。第一個,我們是否計畫分享我們的數據?是的,我們有。而且我們一直在做,也會持續這麼做。

  • And in terms of the kinds of conversations that occur with customers over this, and in a sense, the conversations with the customers are amongst the most straightforward because they understand the issues on all sides, the conversation has really come down to their own experiences and the data. And we are happy to and well-conditioned, well-positioned to have those conversations. We will continue to do so. And as additional data comes out, we are happy to share it with you.

    至於與客戶之間就此所進行的對話類型,某種程度上,與客戶的對話其實是最直接的,因為他們理解各方的議題;對話最終真的回到他們自身的經驗與數據。我們很樂意,也已經做好準備、處於很好的位置來進行這些對話。我們會持續這麼做。而且隨著更多數據出來,我們也很樂意與你分享。

  • That was our last question. In closing, da Vinci surgery has proven safety, efficacy, economic and ergonomic benefits when compared to the open surgical procedures it is replacing. We are steadfast in our conviction in the value that da Vinci has and will bring to the medicine, and we thank you for your support in helping Intuitive expand the benefits of minimally invasive surgery. We look forward to speaking to you again in three months.

    這是我們最後一個問題。最後總結,與其所取代的開腹手術相比,達文西手術已證明具備安全性、有效性、經濟性與人體工學方面的效益。我們堅定相信達文西對醫療的價值,以及未來將帶來的價值;也感謝你們的支持,協助 Intuitive 擴大微創手術的效益。我們期待三個月後再與各位交流。

  • Operator

    Operator

  • Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and using the AT&T Executive Teleconference. You may now disconnect.

    各位女士、先生,今天的電話會議到此結束。感謝各位的參與,並使用 AT&T Executive Teleconference。您現在可以掛線。